title: Soluble CD26 is inversely Associated with Disease Severity in Patients with Chronic Eosinophilic Pneumonia.
abstract: BACKGROUND
  CD26, a multifunctional T cell surface glycoprotein, is a type II transmembrane protein containing only six amino acid residues in its cytoplasmic region. In addition to its membrane form, CD26 exists in plasma in a soluble form (sCD26), which is thought to be the extracellular domain of the molecule cleaved from the cell surface. Recent studies indicated CD26 have an important role in the pathogenesis of asthma, known as Th2 like disease. The function of CD26 in the esosinophlic lung disease is not well understood.
  
  
  METHODS
  Serum sCD26 was determined by enzyme-linked immunosorbent assay in patients with acute eosinophilic pneumonia, chronic eosinophilic pneumonia (CEP), and sarcoidosis, and in healthy volunteers, to establish its value for discriminating between disease entities and as marker of disease activity.
  
  
  RESULTS
  Soluble CD26 was significantly reduced in CEP and was related to disease severity. In particular, sCD26 was inversely correlated with arterial oxygen tension in CEP.
  
  
  CONCLUSIONS
  Serum levels of sCD26 might appear to be useful as a new marker of CEP disease activity.
authors.affiliation: Division of Respiratory Disease, Department of Brain and Nerve Science, Oita University Faculty of Medicine, Ufu-city, Oita 879-5593, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Matsuno
authors.forename: Eishi
authors.initials: E
authors.lastname: Miyazaki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nureki
authors.forename: Takuya
authors.initials: T
authors.lastname: Ueno
authors.forename: Masaru
authors.initials: M
authors.lastname: Ando
authors.forename: Toshihide
authors.initials: T
authors.lastname: Kumamoto
references.citation: N Engl J Med. 1969 Apr 10;280(15):787-98
references.pmid: 5773637
references.citation: Eur Respir J. 2000 Nov;16(5):959-64
references.pmid: 11153599
references.citation: Clin Exp Immunol. 2005 Jan;139(1):13-6
references.pmid: 15606608
references.citation: Blood. 2006 Sep 1;108(5):1602-10
references.pmid: 16670267
references.citation: Regul Pept. 1999 Nov 30;85(1):9-24
references.pmid: 10588446
references.citation: N Engl J Med. 1989 Aug 31;321(9):569-74
references.pmid: 2761601
references.citation: Immunol Lett. 1998 Mar;61(1):7-13
references.pmid: 9580431
references.citation: Clin Exp Immunol. 2000 Aug;121(2):187-92
references.pmid: 10931130
references.citation: Am J Pathol. 2005 Feb;166(2):433-42
references.pmid: 15681827
references.citation: Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12138-43
references.pmid: 11593028
references.citation: J Immunol. 1997 Dec 15;159(12):6070-6
references.pmid: 9550406
references.citation: Cytokine. 2000 Jul;12(7):1136-41
references.pmid: 10880264
references.citation: J Rheumatol. 2002 Sep;29(9):1858-66
references.pmid: 12233879
references.citation: J Immunol. 1990 Dec 15;145(12):3963-71
references.pmid: 1979581
references.citation: Scand J Gastroenterol. 2001 Oct;36(10):1067-72
references.pmid: 11589380
references.citation: Immunol Today. 1999 Aug;20(8):367-75
references.pmid: 10431157
references.citation: Lab Invest. 1995 Nov;73(5):685-90
references.pmid: 7474942
references.citation: Int J Tuberc Lung Dis. 2001 Sep;5(9):868-72
references.pmid: 11573900
references.citation: Clin Exp Immunol. 2005 Jan;139(1):17-24
references.pmid: 15606609